{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:00:36Z","timestamp":1791115236850,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/nrrheum.2014.208","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T07:36:14Z","timestamp":1418715374000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Advances in biomarkers for paediatric rheumatic diseases"],"prefix":"10.1038","volume":"11","author":[{"given":"Alessandro","family":"Consolaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia C.","family":"Varnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"BFnrrheum2014208_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","volume":"22","author":"VG De Gruttola","year":"2001","unstructured":"De Gruttola, V. G. et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin. Trials 22, 485\u2013502 (2001).","journal-title":"Control Clin. Trials"},{"key":"BFnrrheum2014208_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.trsl.2012.01.021","volume":"159","author":"JM Ahearn","year":"2012","unstructured":"Ahearn, J. M., Liu, C. C., Kao, A. H. & Manzi, S. Biomarkers for systemic lupus erythematosus. Transl. Res. 159, 326\u2013342 (2012).","journal-title":"Transl. Res."},{"key":"BFnrrheum2014208_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.rdc.2013.05.001","volume":"39","author":"M Bennett","year":"2013","unstructured":"Bennett, M. & Brunner, H. I. Biomarkers and updates on pediatric lupus nephritis. Rheum. Dis. Clin. North Am. 39, 833\u2013853 (2013).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrrheum2014208_CR4","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1371\/journal.pmed.0050172","volume":"5","author":"TP Klassen","year":"2008","unstructured":"Klassen, T. P., Hartling, L., Craig, J. C. & Offringa, M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 5, e172 (2008).","journal-title":"PLoS Med."},{"key":"BFnrrheum2014208_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/bmm.11.96","volume":"5","author":"J Goldman","year":"2011","unstructured":"Goldman, J., Becker, M. L., Jones, B., Clements, M. & Leeder, J. S. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomark. Med. 5, 781\u2013794 (2011).","journal-title":"Biomark. Med."},{"key":"BFnrrheum2014208_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s11926-013-0406-3","volume":"16","author":"CL Duurland","year":"2014","unstructured":"Duurland, C. L. & Wedderburn, L. R. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 16, 406 (2014).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum2014208_CR7","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390\u2013392 (2004).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli, A. & Martini, A. Juvenile idiopathic arthritis. Lancet 369, 767\u2013778 (2007).","journal-title":"Lancet"},{"key":"BFnrrheum2014208_CR9","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken, B., Albani, S. & Martini, A. Juvenile idiopathic arthritis. Lancet 377, 2138\u20132149 (2011).","journal-title":"Lancet"},{"key":"BFnrrheum2014208_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/rheumatology\/31.9.633","volume":"31","author":"TR Southwood","year":"1992","unstructured":"Southwood, T. R. & Ryder, C. A. Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis? Br. J. Rheumatol. 31, 633\u2013634 (1992).","journal-title":"Br. J. Rheumatol."},{"key":"BFnrrheum2014208_CR11","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology: Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 92, 295\u2013296 (1993).","DOI":"10.1542\/peds.92.2.295"},{"key":"BFnrrheum2014208_CR12","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1542\/peds.2006-0421","volume":"117","author":"J Cassidy","year":"2006","unstructured":"Cassidy, J., Kivlin, J., Lindsley, C. & Nocton, J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 117, 1843\u20131845 (2006).","journal-title":"Pediatrics"},{"key":"BFnrrheum2014208_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","volume":"46","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus, A., Niewerth, M., Ganser, G., Heinz, C. & Minden, K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46, 1015\u20131019 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3899\/jrheum.131494","volume":"41","author":"S Calandra","year":"2014","unstructured":"Calandra, S. et al. Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. J. Rheumatol. 41, 1416\u20131425 (2014).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/art.27284","volume":"62","author":"PJ Hunter","year":"2010","unstructured":"Hunter, P. J. et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 62, 896\u2013907 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR16","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1021\/pr900680w","volume":"8","author":"DS Gibson","year":"2009","unstructured":"Gibson, D. S. et al. Stratification and monitoring of juvenile idiopathic arthritis patients by synovial proteome analysis. J. Proteome Res. 8, 5601\u20135609 (2009).","journal-title":"J. Proteome Res."},{"key":"BFnrrheum2014208_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/rheumatology\/keq362","volume":"50","author":"A Myles","year":"2011","unstructured":"Myles, A. & Aggarwal, A. Expression of Toll-like receptors 2 and 4 is increased in peripheral blood and synovial fluid monocytes of patients with enthesitis-related arthritis subtype of juvenile idiopathic arthritis. Rheumatology (Oxford) 50, 481\u2013488 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR18","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.3899\/jrheum.110352","volume":"38","author":"V Viswanath","year":"2011","unstructured":"Viswanath, V., Myles, A., Dayal, R. & Aggarwal, A. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis. J. Rheumatol. 38, 2482\u20132487 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3899\/jrheum.130924","volume":"41","author":"C Aoki","year":"2014","unstructured":"Aoki, C. et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J. Rheumatol. 41, 1171\u20131177 (2014).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR20","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1002\/art.20631","volume":"50","author":"D Foell","year":"2004","unstructured":"Foell, D. & Roth, J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 50, 3762\u20133771 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","volume":"71","author":"D Holzinger","year":"2012","unstructured":"Holzinger, D. et al. The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann. Rheum. Dis. 71, 974\u2013980 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014208_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.berh.2014.05.002","volume":"28","author":"S Vastert","year":"2014","unstructured":"Vastert, S. & Prakken, B. Update on research and clinical translation on specific clinical areas: from bench to bedside: how insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis. Best. Pract. Res. Clin. Rheumatol. 28, 229\u2013246 (2014).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2014208_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/ard.2006.061853","volume":"66","author":"W de Jager","year":"2007","unstructured":"de Jager, W. et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 66, 589\u2013598 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014208_CR24","first-page":"823","volume":"34","author":"AP Lotito","year":"2007","unstructured":"Lotito, A. P., Campa, A., Silva, C. A., Kiss, M. H. & Mello, S. B. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J. Rheumatol. 34, 823\u2013830 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12014-010-9058-8","volume":"6","author":"XB Ling","year":"2010","unstructured":"Ling, X. B. et al. Urine peptidomic and targeted plasma protein analyses in the diagnosis and monitoring of systemic juvenile idiopathic arthritis. Clin. Proteomics 6, 175\u2013193 (2010).","journal-title":"Clin. Proteomics"},{"key":"BFnrrheum2014208_CR26","first-page":"774","volume":"28","author":"C Scott","year":"2010","unstructured":"Scott, C. et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 28, 774\u2013781 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum2014208_CR27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/rheumatology\/ker165","volume":"50","author":"S Lanni","year":"2011","unstructured":"Lanni, S. et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology (Oxford) 50, 1627\u20131634 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/ard.2009.120840","volume":"69","author":"I Vilca","year":"2010","unstructured":"Vilca, I. et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann. Rheum. Dis. 69, 1479\u20131483 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014208_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","volume":"50","author":"V Papsdorf","year":"2011","unstructured":"Papsdorf, V. & Horneff, G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50, 214\u2013221 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR30","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"MH Otten","year":"2011","unstructured":"Otten, M. H. et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306, 2340\u20132347 (2011).","journal-title":"JAMA"},{"key":"BFnrrheum2014208_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3899\/jrheum.120842","volume":"40","author":"N Solari","year":"2013","unstructured":"Solari, N. et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol. 40, 192\u2013200 (2013).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR32","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505\u20131515 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR33","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","volume":"52","author":"H Moncrieffe","year":"2013","unstructured":"Moncrieffe, H. et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein. Rheumatology (Oxford) 52, 1467\u20131476 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert, S. J. et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66, 1034\u20131043 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2014208_CR35","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell, D. et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266\u20131273 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum2014208_CR36","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","volume":"71","author":"J Gerss","year":"2012","unstructured":"Gerss, J. et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann. Rheum. Dis. 71, 1991\u20131997 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014208_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acr.22248","volume":"66","author":"F Rothmund","year":"2013","unstructured":"Rothmund, F. et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) 66, 949\u2013955 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014208_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli, A., Grom, A. A., Behrens, E. M. & Cron, R. Q. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 13, 289\u2013298 (2012).","journal-title":"Genes Immun."},{"key":"BFnrrheum2014208_CR39","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens, E. M., Beukelman, T., Paessler, M. & Cron, R. Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34, 1133\u20131138 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","volume":"56","author":"J Bleesing","year":"2007","unstructured":"Bleesing, J. et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor \u03b1-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56, 965\u2013971 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1309\/AJCPMD5TJEFOOVBW","volume":"141","author":"C Ho","year":"2014","unstructured":"Ho, C. et al. Marrow assessment for haemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am. J. Clin. Pathol. 141, 62\u201371 (2014).","journal-title":"Am. J. Clin. Pathol."},{"key":"BFnrrheum2014208_CR42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","volume":"146","author":"A Ravelli","year":"2005","unstructured":"Ravelli, A. et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 146, 598\u2013604 (2005).","journal-title":"J. Pediatr."},{"issue":"Suppl. 1","key":"BFnrrheum2014208_CR43","doi-asserted-by":"publisher","first-page":"O1","DOI":"10.1186\/1546-0096-12-S1-O1","volume":"12","author":"F Minoia","year":"2014","unstructured":"Minoia, F. et al. Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis [abstract]. Pediatr. Rheumatol. 12 (Suppl. 1) O1 (2014).","journal-title":"Pediatr. Rheumatol."},{"key":"BFnrrheum2014208_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/1756-185X.12196","volume":"17","author":"VV Reddy","year":"2014","unstructured":"Reddy, V. V., Myles, A., Cheekatla, S. S., Singh, S. & Aggarwal, A. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int. J. Rheum. Dis. 17, 261\u2013267 (2014).","journal-title":"Int. J. Rheum. Dis."},{"key":"BFnrrheum2014208_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3899\/jrheum.121131","volume":"40","author":"M Gorelik","year":"2013","unstructured":"Gorelik, M. et al. Follistatin-like protein 1 and the ferritin\/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J. Rheumatol. 40, 1191\u20131199 (2013).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","volume":"61","author":"M Shimizu","year":"2013","unstructured":"Shimizu, M., Nakagishi, Y. & Yachie, A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61, 345\u2013348 (2013).","journal-title":"Cytokine"},{"key":"BFnrrheum2014208_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1189\/jlb.0602313","volume":"73","author":"JA Gracie","year":"2003","unstructured":"Gracie, J. A., Robertson, S. E. & McInnes, I. B. Interleukin-18. J. Leukoc. Biol. 73, 213\u2013224 (2003).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrrheum2014208_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0167-5699(00)01648-0","volume":"21","author":"IB McInnes","year":"2000","unstructured":"McInnes, I. B., Gracie, J. A., Leung, B. P., Wei, X. Q. & Liew, F. Y. Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol. Today 21, 312\u2013315 (2000).","journal-title":"Immunol. Today"},{"key":"BFnrrheum2014208_CR49","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/art.24750","volume":"60","author":"W de Jager","year":"2009","unstructured":"de Jager, W. et al. Defective phosphorylation of interleukin-18 receptor \u03b2 causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2782\u20132793 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR50","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/978-3-642-02202-9_159","volume-title":"Textbook of Clinical Pediatrics","author":"B Lattanzi","year":"2012","unstructured":"Lattanzi, B. & Ravelli, A. in Textbook of Clinical Pediatrics (eds Elzouki, A. Y. et al.), 1629\u20131641 (Springer, 2012)."},{"key":"BFnrrheum2014208_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241\u2013250 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014208_CR52","first-page":"187","volume":"65","author":"BH Rovin","year":"2007","unstructured":"Rovin, B. H., Birmingham, D. J., Nagaraja, H. N., Yu, C. Y. & Hebert, L. A. Biomarker discovery in human SLE nephritis. Bull. NYU Hosp. Jt. Dis. 65, 187\u2013193 (2007).","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"BFnrrheum2014208_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0961203311422093","volume":"21","author":"I Batal","year":"2012","unstructured":"Batal, I. et al. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. Lupus 21, 13\u201326 (2012).","journal-title":"Lupus"},{"key":"BFnrrheum2014208_CR54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/0961203312444496","volume":"21","author":"V Dhir","year":"2012","unstructured":"Dhir, V. Is cellular C4d a good biomarker for SLE nephritis? Lupus 21, 1036 (2012).","journal-title":"Lupus"},{"key":"BFnrrheum2014208_CR55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00467-010-1720-x","volume":"26","author":"M Edelbauer","year":"2011","unstructured":"Edelbauer, M. et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr. Nephrol. 26, 401\u2013410 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrrheum2014208_CR56","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1097\/01.ASN.0000129114.92265.32","volume":"15","author":"SM Hewitt","year":"2004","unstructured":"Hewitt, S. M., Dear, J. & Star, R. A. Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 15, 1677\u20131689 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014208_CR57","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2741\/2731","volume":"13","author":"BH Rovin","year":"2008","unstructured":"Rovin, B. H. The chemokine network in systemic lupus erythematous nephritis. Front. Biosci. 13, 904\u2013922 (2008).","journal-title":"Front. Biosci."},{"key":"BFnrrheum2014208_CR58","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1681\/ASN.2004080658","volume":"16","author":"BH Rovin","year":"2005","unstructured":"Rovin, B. H. et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16, 467\u2013473 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014208_CR59","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3899\/jrheum.081112","volume":"36","author":"AN Kiani","year":"2009","unstructured":"Kiani, A. N. et al. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J. Rheumatol. 36, 2224\u20132230 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR60","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/art.20266","volume":"50","author":"M Tucci","year":"2004","unstructured":"Tucci, M. et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 50, 1842\u20131849 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR61","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/0961203311431249","volume":"21","author":"L Watson","year":"2012","unstructured":"Watson, L. et al. Urinary monocyte chemoattractant protein 1 and \u03b1 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21, 496\u2013501 (2012).","journal-title":"Lupus"},{"key":"BFnrrheum2014208_CR62","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.4049\/jimmunol.179.10.7166","volume":"179","author":"T Wu","year":"2007","unstructured":"Wu, T. et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 179, 7166\u20137175 (2007).","journal-title":"J. Immunol."},{"key":"BFnrrheum2014208_CR63","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S8756-3282(02)00829-3","volume":"31","author":"DT Graves","year":"2002","unstructured":"Graves, D. T., Alsulaimani, F., Ding, Y. & Marks, S. C. Jr. Developmentally regulated monocyte recruitment and bone resorption are modulated by functional deletion of the monocytic chemoattractant protein-1 gene. Bone 31, 282\u2013287 (2002).","journal-title":"Bone"},{"key":"BFnrrheum2014208_CR64","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/ki.2008.316","volume":"74","author":"X Zhang","year":"2008","unstructured":"Zhang, X. et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 74, 799\u2013807 (2008).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014208_CR65","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00011-007-6147-x","volume":"56","author":"S Tian","year":"2007","unstructured":"Tian, S. et al. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm. Res. 56, 304\u2013310 (2007).","journal-title":"Inflamm. Res."},{"key":"BFnrrheum2014208_CR66","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/ndt\/gfk102","volume":"21","author":"RW Chan","year":"2006","unstructured":"Chan, R. W. et al. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol. Dial. Transplant. 21, 1534\u20131540 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrrheum2014208_CR67","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1074\/jbc.M413192200","volume":"280","author":"JA Gwira","year":"2005","unstructured":"Gwira, J. A. et al. Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. J. Biol. Chem. 280, 7875\u20137882 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2014208_CR68","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/art.22008","volume":"54","author":"HI Brunner","year":"2006","unstructured":"Brunner, H. I. et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 54, 2577\u20132584 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR69","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00467-013-2668-4","volume":"29","author":"L Watson","year":"2014","unstructured":"Watson, L. et al. Urine biomarkers for monitoring juvenile lupus nephritis: a prospective longitudinal study. Pediatr. Nephrol. 29, 397\u2013405 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrrheum2014208_CR70","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1002\/art.24751","volume":"60","author":"CH Hinze","year":"2009","unstructured":"Hinze, C. H. et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 60, 2772\u20132781 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR71","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00467-007-0685-x","volume":"23","author":"M Suzuki","year":"2008","unstructured":"Suzuki, M. et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr. Nephrol. 23, 403\u2013412 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrrheum2014208_CR72","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2741\/1395","volume":"9","author":"S Campbell","year":"2004","unstructured":"Campbell, S., Michaelson, J., Burkly, L. & Putterman, C. The role of TWEAK\/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front. Biosci. 9, 2273\u20132284 (2004).","journal-title":"Front. Biosci."},{"key":"BFnrrheum2014208_CR73","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.4049\/jimmunol.176.3.1889","volume":"176","author":"S Campbell","year":"2006","unstructured":"Campbell, S. et al. Proinflammatory effects of TWEAK\/Fn14 interactions in glomerular mesangial cells. J. Immunol. 176, 1889\u20131898 (2006).","journal-title":"J. Immunol."},{"key":"BFnrrheum2014208_CR74","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaut.2006.12.003","volume":"27","author":"N Schwartz","year":"2006","unstructured":"Schwartz, N. et al. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 27, 242\u2013250 (2006).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2014208_CR75","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/ar2816","volume":"11","author":"N Schwartz","year":"2009","unstructured":"Schwartz, N. et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicentre cohort study. Arthritis Res. Ther. 11, R143 (2009).","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl. 11","key":"BFnrrheum2014208_CR76","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1002\/art.38494","volume":"66","author":"K Abulaban","year":"2014","unstructured":"Abulaban, K. et al. A78: urine biomarkers role in predicting the future development of renal functional loss with lupus nephritis in children and adults. Arthritis Rheumatol. 66 (Suppl. 11), S111 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2014208_CR77","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.ki.5000132","volume":"69","author":"Y Avihingsanon","year":"2006","unstructured":"Avihingsanon, Y. et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int. 69, 747\u2013753 (2006).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014208_CR78","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.4049\/jimmunol.179.10.7166","volume":"179","author":"T Wu","year":"2007","unstructured":"Wu, T. et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 179, 7166\u20137175 (2007).","journal-title":"J. Immunol."},{"key":"BFnrrheum2014208_CR79","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/rheumatology\/kep074","volume":"48","author":"G Wang","year":"2009","unstructured":"Wang, G. et al. Urinary FOXP3 mRNA in patients with lupus nephritis\u2014relation with disease activity and treatment response. Rheumatology (Oxford) 48, 755\u2013760 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR80","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0961203306071873","volume":"15","author":"AM Hammad","year":"2006","unstructured":"Hammad, A. M., Youssef, H. M. & El-Arman, M. M. Transforming growth factor \u03b2 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis. Lupus 15, 608\u2013612 (2006).","journal-title":"Lupus"},{"key":"BFnrrheum2014208_CR81","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00467-007-0608-x","volume":"22","author":"M Suzuki","year":"2007","unstructured":"Suzuki, M. et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr. Nephrol. 22, 2047\u20132057 (2007).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrrheum2014208_CR82","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1203\/PDR.0b013e31819e4305","volume":"65","author":"M Suzuki","year":"2009","unstructured":"Suzuki, M. et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr. Res 65, 530\u2013536 (2009).","journal-title":"Pediatr. Res"},{"key":"BFnrrheum2014208_CR83","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/art.34426","volume":"64","author":"HI Brunner","year":"2012","unstructured":"Brunner, H. I. et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 64, 2687\u20132697 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR84","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.berh.2009.07.007","volume":"23","author":"LR Wedderburn","year":"2009","unstructured":"Wedderburn, L. R. & Rider, L. G. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best. Pract. Res. Clin. Rheumatol. 23, 665\u2013678 (2009).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2014208_CR85","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1001\/jama.2010.1977","volume":"305","author":"LG Rider","year":"2011","unstructured":"Rider, L. G. & Miller, F. W. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305, 183\u2013190 (2011).","journal-title":"JAMA"},{"key":"BFnrrheum2014208_CR86","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014208_CR87","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403\u2013407 (1975).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014208_CR88","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/rheumatology\/kel025","volume":"45","author":"VE Brown","year":"2006","unstructured":"Brown, V. E., Pilkington, C. A., Feldman, B. M. & Davidson, J. E. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford) 45, 990\u2013993 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR89","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/rheumatology\/ker262","volume":"50","author":"WR Davis","year":"2011","unstructured":"Davis, W. R. et al. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology (Oxford) 50, 2237\u20132244 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR90","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1136\/annrheumdis-2012-202915","volume":"73","author":"C Malattia","year":"2014","unstructured":"Malattia, C. et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann. Rheum. Dis. 73, 1083\u20131090 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014208_CR91","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","volume":"48","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena, H., Betteridge, Z. E. & McHugh, N. J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48, 607\u2013612 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR92","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/ar4198","volume":"15","author":"SL Tansley","year":"2013","unstructured":"Tansley, S. L., McHugh, N. J. & Wedderburn, L. R. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res. Ther. 15, 211 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014208_CR93","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","volume":"47","author":"H Gunawardena","year":"2008","unstructured":"Gunawardena, H. et al. Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47, 324\u2013328 (2008).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014208_CR94","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider, L. G. et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92, 223\u2013243 (2013).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum2014208_CR95","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.rdc.2013.06.001","volume":"39","author":"LG Rider","year":"2013","unstructured":"Rider, L. G., Katz, J. D. & Jones, O. Y. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 39, 877\u2013904 (2013).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrrheum2014208_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","volume":"87","author":"A Bingham","year":"2008","unstructured":"Bingham, A. et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 87, 70\u201386 (2008).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum2014208_CR97","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.3899\/jrheum.090461","volume":"36","author":"G Espada","year":"2009","unstructured":"Espada, G., Maldonado Cocco, J. A., Fertig, N. & Oddis, C. V. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J. Rheumatol. 36, 2547\u20132551 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR98","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena, H. et al. Autoantibodies to a 140-kD protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 60, 1807\u20131814 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR99","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/acr.22212","volume":"66","author":"AM Huber","year":"2014","unstructured":"Huber, A. M. et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. (Hoboken) 66, 732\u2013740 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014208_CR100","first-page":"927","volume":"35","author":"KA Rouster-Stevens","year":"2008","unstructured":"Rouster-Stevens, K. A. & Pachman, L. M. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J. Rheumatol. 35, 927\u2013929 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014208_CR101","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato, S. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193\u20132200 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014208_CR102","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","volume":"158","author":"I Kobayashi","year":"2011","unstructured":"Kobayashi, I. et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J. Pediatr. 158, 675\u2013677 (2011).","journal-title":"J. Pediatr."},{"key":"BFnrrheum2014208_CR103","doi-asserted-by":"publisher","first-page":"R138","DOI":"10.1186\/ar4600","volume":"16","author":"S Tansley","year":"2014","unstructured":"Tansley, S. et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther. 16, R138 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014208_CR104","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal, R. et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 66, 740\u2013749 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum2014208_CR105","first-page":"234","volume":"38","author":"D Peixoto","year":"2013","unstructured":"Peixoto, D., Costa, J., Ferretti, M., Malattia, C. & Martini, A. New autoantibodies and their clinical associations in juvenile myositis\u2014a systematic review. Acta Reumatol. Port. 38, 234\u2013241 (2013).","journal-title":"Acta Reumatol. Port."},{"key":"BFnrrheum2014208_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","volume":"92","author":"M Shah","year":"2013","unstructured":"Shah, M. et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92, 25\u201341 (2013).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrrheum2014208_CR107","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/rheumatology\/kem265","volume":"46","author":"LR Wedderburn","year":"2007","unstructured":"Wedderburn, L. R. et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 46, 1786\u20131791 (2007).","journal-title":"Rheumatology (Oxford)"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.208","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:35:18Z","timestamp":1684470918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFnrrheum2014208"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.208","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,16]]},"assertion":[{"value":"16 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}